Plitidepsin to treat multiple myeloma in AustraliaFebruary 5, 2019
The Australian Regulatory Agency (TGA) has given approval plitidepsin (Aplidin) for the treatment of multiple myeloma in combination with dexamethasone.
The indication has been approved for the treatment of patients that relapse after three lines of treatment, including proteasome inhibitors or immunomodulators. It can also be administered as 3rd line treatment when the patient has already received two prior lines and is refractory or intolerant to proteasome inhibitors or immunomodulators.
Plitidepsin is an anticancer agent of marine origin, originally obtained from the ascidian Aplidium albicans. It specifically binds to the eEF1A2 and targets the non -canonical role of this protein, resulting in tumour cell death via apoptosis. Plitidepsin has received orphan drug designation in the EU and the US.